Taysha Gene Therapies Total Liabilities and Share Holders Equity 2020-2024 | TSHA
Taysha Gene Therapies total liabilities and share holders equity from 2020 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Taysha Gene Therapies Annual Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2023 |
$173 |
| 2022 |
$126 |
| 2021 |
$214 |
| 2020 |
$259 |
| 2019 |
$0 |
Taysha Gene Therapies Quarterly Total Liabilities and Share Holders Equity
(Millions of US $) |
| 2024-06-30 |
$200 |
| 2024-03-31 |
$153 |
| 2023-12-31 |
$173 |
| 2023-09-30 |
$196 |
| 2023-06-30 |
$82 |
| 2023-03-31 |
$102 |
| 2022-12-31 |
$126 |
| 2022-09-30 |
$111 |
| 2022-06-30 |
$142 |
| 2022-03-31 |
$166 |
| 2021-12-31 |
$214 |
| 2021-09-30 |
$241 |
| 2021-06-30 |
$242 |
| 2021-03-31 |
$243 |
| 2020-12-31 |
$259 |
| 2020-09-30 |
$279 |
| 2020-06-30 |
$0 |
| 2020-03-31 |
$0 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.449B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
